Travere Therapeutics, Inc. Common Stock
TVTX
$62.45
-0.49%
Travere Therapeutics is a biopharmaceutical company focused on developing and delivering life-changing therapies for rare kidney, liver, and metabolic diseases. Its lead product, sparsentan (marketed as Filspari), targets rare kidney disorders such as IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), with a pipeline also including pegtibatinase for homocystinuria (HCU). The company holds a distinct position as a niche player in the rare disease space, leveraging a specialized commercial infrastructure and a late-stage pipeline. The current investor narrative centers on the commercial ramp of Filspari, which has driven a dramatic re-rating of the stock over the past year, alongside ongoing regulatory and clinical developments that could expand its label and addressable market.…
TVTX
Travere Therapeutics, Inc. Common Stock
$62.45
Investment Opinion: Should I buy TVTX Today?
Based on the analysis, I rate TVTX as a Buy. The thesis is that Travere's explosive revenue growth, driven by Filspari, combined with a strong pipeline and potential label expansion, justifies the premium valuation. The analyst consensus is 'Strong Buy' with an average target of $59.14, implying 5.8% upside, and the high target of $70 suggests even more upside. The company's high gross margin of 97.9% and low PEG ratio of 0.79 support the growth narrative.
Sign up to view all
TVTX 12-Month Price Forecast
The AI assessment is bullish on TVTX, driven by exceptional revenue growth and high gross margins. The low PEG ratio indicates that the stock is not overvalued relative to its growth potential. However, confidence is medium due to the high debt and negative operating margin, which introduce financial risk. The stance would be upgraded to high confidence if the company achieves positive operating cash flow or secures FSGS approval. Conversely, a downgrade to neutral would occur if revenue growth decelerates below 50% or if regulatory setbacks occur.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Travere Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $60.36 and implied upside of -3.4% versus the current price.
Average Target
$60.36
0 analysts
Implied Upside
-3.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$43 - $75
Analyst target range
Analyst coverage is robust, with 14 analysts covering TVTX and a consensus recommendation of 'Strong Buy' (mean rating of 1.27 on a 1-5 scale). The average price target is $59.14, implying approximately 5.8% upside from the current price of $55.89. The distribution is overwhelmingly bullish, with no sell ratings and only a few holds, reflecting high conviction in the company's commercial execution and pipeline prospects. The target range spans from a low of $43.00 to a high of $70.00, indicating a wide dispersion of views on the stock's fair value. The high target of $70 suggests expectations of continued strong sales growth and potential label expansion, while the low target of $43 may reflect concerns about competition, regulatory setbacks, or slower-than-expected adoption. The wide spread (27% between low and high) signals elevated uncertainty, but the overall bullish tilt and strong buy consensus underscore the market's positive outlook on Travere's growth trajectory.
Bulls vs Bears: TVTX Investment Factors
Travere presents a compelling growth story with explosive revenue growth, high gross margins, and a strong analyst consensus. However, the stock is trading at a premium valuation, the company is not yet profitable, and it carries significant debt. The bull case is supported by the potential for label expansion and the low PEG ratio, while the bear case is anchored on valuation concerns and operational risks. Currently, the bull case has stronger evidence given the accelerating revenue and clear catalysts, but the key tension is whether the market's high expectations for Filspari's commercial success can be met. If sales growth decelerates or regulatory setbacks occur, the premium valuation could quickly unwind.
Bullish
- Explosive Revenue Growth: Travere's most recent quarterly revenue is approximately $441.7 million, reflecting year-over-year growth of over 100%. This rapid acceleration is driven by the successful commercial launch of Filspari, indicating strong market adoption and a clear path to blockbuster sales.
- High Gross Margin of 97.9%: The company's gross margin is exceptionally high at 97.9%, typical of specialty pharmaceuticals. This allows for significant operating leverage as revenue scales, meaning a large portion of incremental sales will drop to the bottom line, supporting future profitability.
- Strong Buy Consensus with 5.8% Upside: Analysts are overwhelmingly bullish, with a consensus rating of 'Strong Buy' (mean 1.27) and an average price target of $59.14, implying 5.8% upside from the current price of $55.89. The high target of $70 suggests potential for further gains if label expansion and sales growth materialize.
- Potential Label Expansion into FSGS: Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS), a rare kidney disorder. Regulatory approval for this indication would significantly expand the addressable market and provide a major catalyst for revenue growth beyond IgAN.
Bearish
- Negative Operating Margin of -12.8%: Despite high gross margins, Travere's operating margin is negative at -12.8%, reflecting heavy investment in sales, marketing, and R&D. This means the company is still burning cash, and profitability is not yet achieved, which could pressure the stock if growth slows.
- Elevated PS Ratio of 6.95x: The price-to-sales ratio of 6.95x is significantly higher than the biotech industry average of 4-5x, implying a premium of 40-70%. This valuation leaves little room for error; any disappointment in sales growth could lead to multiple compression.
- High Debt-to-Equity of 2.86: The debt-to-equity ratio of 2.86 indicates a high level of leverage, which increases financial risk. This is particularly concerning for a company that is not yet profitable, as debt servicing could strain cash flows if revenue growth falters.
- Recent Price Decline of 2.4%: The stock recently declined by 2.4% in a single day, and the 1-month relative strength is -0.97, indicating underperformance versus the S&P 500. This suggests some near-term profit-taking or investor caution after the massive run-up, which could continue.
TVTX Technical Analysis
TVTX has exhibited a powerful sustained uptrend over the past year, with the stock price surging 261.7% over the trailing twelve months. The current price of $55.89 sits near the upper end of its 52-week range, at approximately 93% of the distance from the low of $15.03 to the high of $60.10. This positioning near the highs reflects strong momentum and investor optimism, though it also raises the risk of overextension and potential profit-taking. The stock has outperformed the S&P 500 dramatically, with relative strength of 243.6% over the past year, underscoring its leadership within the biotech sector.
Beta
1.04
1.04x market volatility
Max Drawdown
-33.5%
Largest decline past year
52-Week Range
$16-$65
Price range past year
Annual Return
+262.2%
Cumulative gain past year
| Period | TVTX Return | S&P 500 |
|---|---|---|
| 1m | +8.0% | +2.8% |
| 3m | +46.6% | +4.2% |
| 6m | +110.2% | +11.3% |
| 1y | +262.2% | +21.5% |
| ytd | +58.0% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TVTX Fundamental Analysis
Travere's revenue trajectory is accelerating, driven by the commercial launch of Filspari. The company's most recent quarterly revenue (implied from annual estimates) is approximately $441.7 million, reflecting a year-over-year growth rate of over 100% as the drug gains market traction. The multi-quarter trend shows sequential acceleration, with revenue ramping from earlier quarters as patient uptake expands. This growth is primarily driven by Filspari's adoption in IgAN, with potential label expansion into FSGS representing a significant future catalyst. The company's gross margin is exceptionally high at 97.9%, reflecting the low cost of goods for specialty pharmaceuticals, but operating margin remains negative at -12.8% due to heavy investment in sales, marketing, and R&D.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TVTX Overvalued?
Given that Travere's trailing net income is negative (EPS of -$0.0075), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio stands at 6.95x, which is elevated relative to the broader biotech industry average of around 4-5x, indicating a premium of approximately 40-70%. This premium is justified by the company's high growth rate and the potential for blockbuster sales of Filspari. The forward PE of 11.7x, based on estimated EPS of $4.80, implies that the market expects a dramatic earnings inflection as revenue scales and operating leverage kicks in, which is a common pattern for successful rare disease drugs.
PE
-68.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
164.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's negative operating margin of -12.8% indicates ongoing cash burn, which is typical for a growth-stage biotech but raises concerns about sustainability. The high debt-to-equity ratio of 2.86 amplifies financial risk, especially if revenue growth slows or if the company needs to raise additional capital. Revenue concentration in a single product, Filspari, means that any commercial hiccup could severely impact financials. The company's reliance on continued growth to justify its valuation is a key risk, as any miss in sales expectations could lead to a sharp de-rating.